Clinical Trial Results:
A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg, 400mcg, 600mcg and 800mcg Administered Once Daily in the Morning and Fluticasone Propionate 500mcg BID via DISKUS Inhalation Powder Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (≥12 years old) with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy
Summary
|
|
EudraCT number |
2005-001122-87 |
Trial protocol |
LT LV |
Global completion date |
05 Jan 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Dec 2018
|
First version publication date |
16 Dec 2018
|
Other versions |
|
Summary report(s) |
Cancelled before Active Statement |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.